ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harpoon Therapeutics Granted Orphan Drug Designation for Multiple Myeloma Treatment
January 20, 2021Harpoon Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets ... -
Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer
January 11, 2021Harpoon Therapeutics announced the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated ...
Pharma Sources Insight January 2025
